Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01164904 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01164904 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 72 participants.
The verdict
NCT01164904, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)
Interventions
- DRUG Amg 181
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01164904
The ClinicalTrials.gov registry entry for NCT01164904 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amg 181 is the first listed.
NCT01164904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01164904 about?
NCT01164904 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis". To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)
What is the current status of trial NCT01164904?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2010-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01164904?
The interventions under investigation include: Amg 181 (DRUG).
Who is sponsoring clinical trial NCT01164904?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.